Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PH46A
- Development stage
- Phase 1
- Lead developer
- Trino Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**PH46A** is a first-in-class **1,2-indane dimer** with potent anti-inflammatory and immune-modulating activity, specifically the *N*-glucamine salt of the *(1S,2S)-enantiomer* of PH46. Developed as a novel therapeutic for **inflammatory and autoimmune diseases**, particularly **inflammatory bowel disease (IBD)**, it demonstrates efficacy in murine models of colitis (DSS and IL-10^−/−^*), reducing colon cytokines (TNF-α, IL-6, IL-1β) and histological damage. PH46A inhibits **5-lipoxygenase (5-LOX)**, nitric oxide (NO) production, and cytokines (IL-6, TNF-α, IL-8, IFN-γ) in vitro without cytotoxicity, dissociating in solution to its active PH46 form.[1][2]
- Other names
- PH46PH-46PH 46
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on PH46A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PH46A.